Table 1

 Clinical and biological characteristics

Patients with ALSNeurological controls
HypoxaemicNormoxaemicHypoxaemicNormoxaemic
Clinical and biological characteristics of the four groups of subjects. Data are stated as median values and (first and third quartiles), except *mean (SD). B, bulbar; S, spinal; CSF, cerebrospinal fluid; VEGF, vascular endothelial growth factor. †Significant difference (p<0.05) between hypoxaemic and normoxaemic patients with ALS; ‡significant difference (p<0.05) between hypoxaemic patients with ALS and hypoxaemic neurological controls; §significant difference (p<0.05) between hypoxaemic and normoxaemic neurological controls.
No. of patients10101010
Age (years)64.4 (31–78)67.5 (57–77)73.4 (63–84)67 (28–80)
Sex ratio6 F/4 M3 F/7 M1 F/9 M3 F/7 M
Disease duration DD (months)20.6 (9–30)17.7 (9–27)
Onset form (DD)*7 B (19.4 (7.1)); 3 S (20.6 (7.64))4 B (19.75 (8.1)); 6 S (14.6 (6.2))
El Escorial category6 definite/4 probable4 definite/6 probable
Total serum protein (g/l)70 (64–77)72 (61–82)70.8 (56–80)70.9 (65–76)
Serum albumin (g/l)43 (35–58)45.4 (38–56)39 (36–42)41.3 (35.2–48.5)
Total CSF protein (g/l)0.54 (0.3–0.8)0.48 (0.4–0.6)0.57 (0.4–0.8)0.64 (0.46–1)
PaO2 mean level (mm Hg)73.5 (67–77)†100.5 (96–103)†70 (64–74)§95 (94–101)§
Mean nocturnal SaO2 level (%)88 (80–91)91.2 (87–96)81.3 (66–91)90 (88–92)
SaO2 90 (% of night time ⩽90%)4 (2–9)†0 (0–0)3 (1–5)§0 (0–1)
PaCO2 mean level (mm Hg)43.7 (39–45.9)39 (28.2–45)41.6 (26.4–47.8)41.5 (38–46)
CSF VEGF level (pg/ml)3 (2.2–4.7)†‡6 (5.2–7)†9.5 (8.2–10.7)‡§5.5 (3.25–7.75)§
Plasma VEGF level (pg/ml)167 (120–368)154 (110–255)266 (240–583)224 (131–323)